Glaxosmithkline Plc (GSK) 47.94 $GSK
Tracking Tweedy Browne's Portfolio - Q4 2014 Update
John Vincent - at Seeking Alpha - Sat Feb 14, 11:31AM CST
KOF: 84.71 (+0.59), DNOW: 25.64 (+0.70), CNQ: 31.63 (+0.45), WMT: 85.81 (-0.08), GOOG: 549.01 (+6.08), DEO: 113.89 (-1.40), BSBR: 5.07 (+0.19), NOV: 53.36 (+0.80), FII: 35.09 (+0.20), CSCO: 29.43 (-0.03), MA: 87.14 (-0.38), PSX: 76.62 (+1.51), TMK: 54.05 (+0.35), UN: 42.28 (-0.30), HAL: 44.19 (+1.42), AGCO: 49.78 (+0.97), COP: 69.88 (+1.84), WFC: 55.33 (+0.47), GSK: 47.94 (+1.99), UL: 43.03 (-0.17), CTWS: 37.37 (-0.03), NWLI: 245.15 (+0.45), RDS.A: 66.32 (+0.97), ANAT: 104.90 (-0.10), BRK.B: 148.34 (-1.45), BRK.A: 222,555.00 (-1,905.00), NVS: 102.20 (-0.17), MMM: 165.94 (+0.03), LMT: 196.95 (-0.53), UNF: 121.82 (-0.50), XOM: 93.37 (+1.00), SHEN: 30.36 (+0.37), JNJ: 99.62 (+1.18), GOOGL: 551.16 (+5.15), BK: 39.20 (-0.21), UNP: 122.60 (-1.23), JOY: 44.14 (+0.35), DVN: 66.47 (+0.69), AXP: 78.08 (-2.40), EMR: 58.68 (+0.08), HSBC: 46.13 (-0.01), ITW: 98.26 (+0.48), PM: 82.87 (-0.82), BRO: 33.01 (+0.20), TOT: 54.14 (-0.36), USB: 45.07 (-0.05), BAX: 70.39 (+0.31), CMCSA: 59.47 (+1.09), VZ: 49.31 (-0.21)
The Fed Must Tolerate Higher Asset Prices To Achieve Higher Wages
Joe Leider - Seeking Alpha - Sat Feb 14, 12:45AM CST
I've been thinking a lot about inflation, banks and China. After reading "Gold, France, and the Great Depression, 1919-1932", I was wondering how the western world's "secular stagnation" could be related to China's rise. Before...
T: 34.66 (+0.05), GSK: 47.94 (+1.99), VZ: 49.31 (-0.21)
After Yesterday's Rally of 4.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Feb 13, 3:58PM CST
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $47.38 to a high of $47.96. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $46.30 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 47.94 (+1.99)
GlaxoSmithKline Set to Possibly Pullback After Yesterday's Rally of 4.33%
Comtex SmarTrend(R) - Fri Feb 13, 3:57PM CST
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $47.38 to a high of $47.96. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $46.30 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 47.94 (+1.99)
Jim Cramer's Stop Trading: Apache Has Room to Rise, J&J Takes It on the Chin
at The Street - Fri Feb 13, 12:19PM CST
Jim Cramer says independent energy company Apache is one to watch on great production, growth and a Merrill Lynch upgrade.
JNJ: 99.62 (+1.18), PXD: 157.85 (+9.71), APA: 67.05 (+2.47), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up
at Investor's Business Daily - Fri Feb 13, 9:41AM CST
Stocks opened higher in soft trade Friday as generally positive news out of Europe, rising oil prices and a welter of fourth-quarter earnings surprises bolstered early trade. The Nasdaq and the Dow Jones industrial average pulsed up 0.2% apiece. The...
VIP: 5.37 (+0.51), CAVM: 62.86 (-0.55), BIDU: 212.13 (+7.11), AKS: 4.87 (+0.39), TSM: 24.84 (+0.37), NTAP: 38.22 (+1.32), GSK: 47.94 (+1.99), X: 26.36 (+1.12), MT: 11.20 (+0.74)
GlaxoSmithKline +3.8% after UBS turns bullish
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:30AM CST
GSK: 47.94 (+1.99)
1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Upgrade Alert for GlaxoSmithKline (GSK)
Comtex SmarTrend(R) - Fri Feb 13, 6:57AM CST
GlaxoSmithKline (NYSE:GSK) was upgraded from Sell to Buy at UBS today. The stock closed yesterday at $45.95 on volume of 3.5 million shares, below average daily volume of 4.2 million. GlaxoSmithKline plc is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. The Group, which also provides laboratory testing and disease management services, specializes in treatments for respiratory, central nervous system, gastro-intestinal and genetic disorders
GSK: 47.94 (+1.99)
Analysis of Chinese Liver Disease Drug Industry 2015
M2 - Fri Feb 13, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/lh55pz/analysis_of) has announced the addition of the "Analysis of Chinese Liver Disease Drug Industry 2015" report to their offering. Liver disease drug market competition in China is fierce. China's liver disease drug market can be divided into imported drugs and home-made drugs according to the drug producing area. Imported drugs are mainly represented by GlaxoSmithKline and Bristol-Myers Squibb, etc.; the main production enterprises of home-made drugs include Chia Tai Tianqing Pharmaceutical Group, TIPR Pharmaceutical Responsible Company, Fujian Cosunter Pharmaceutical Company, etc. Hepatobiliary system drug has gradually become a variety that costs a large amount of money and it is the third largest one that ranks only second to anti-peptic ulcer and diabetes drug in the digestion metabolism category. In terms of the structure of drug, anti-viral drugs and free regulating drugs account for 30% of liver disease drug, auxiliary drugs account for 25% and Chinese medicine account for 36%. The sales volume of China liver disease drug in hospital market is increasing. Before 2009, as a result of the continuous introduction of new products, new specifications and new dosage form products, the growth of sales was comparatively large, while its growth began to slow down from 2010. On the one hand, it is due to the hepatitis B vaccination rate has been increased significantly in recent years and the decrease of the expansion speed of hepatitis B patients; on the other hand, the growth of sales has entered a smooth stage. The data issued by China Competition Information shows that, the scale of China liver disease drug market is close to RMB 43 billion in 2013. Key Topics Covered: CHAPTER I RELATED OVERVIEW OF LIVER DISEASE DRUG CHAPTER II ANALYSIS OF THE OPERATION SITUATION OF GLOBAL DRUGS FOR THE LIVER DISEASE MARKETS IN 2013 CHAPTER III ANALYSIS OF MARKET DEVELOPMENT ENVIRONMENT OF CHINA'S LIVER DISEASE DRUG INDUSTRY IN 2013-2014 SECTION IV THE LEVEL AND FEATURES OF LIVER DISEASE MEDICATION TECHNIQUE CHAPTER IV HEPATITIS INCIDENCE IN CHINA AND ANALYSIS OF THE STATISTICS OF ITS PREVALENCE IN 2013 CHAPTER V TYPES OF LIVER MEDICINE CHAPTER VI DEEP RESEARCH OF CHINA LIVER MEDICATION MARKET IN 2013 CHAPTER VII OBSERVATION ON DYNAMICS OF SEGMENT MARKET OF LIVER DISEASE DRUGS 2013 CHAPTER VIII CHINA HEPATITIS B VACCINE MARKET ANALYSIS IN 2013 CHAPTER IX COMPARATIVE ANALYSIS OF MAIN ANTI-HEPATITIS DRUGS IN CHINA IN 2012-2013 CHAPTER X CLINICAL APPLICATION OF LIVERISH RESEARCH RESULTS AND DYNAMIC TRACING OF THE NEWEST CHAPTER XI ANALYSIS OF DYNAMIC AND TREND COMPETITION FOR CHINA'S LIVER DISEASE DRUG MARKET IN 2013 CHAPTER XII SWOT ANALYSIS OF CHINA'S LIVER DISEASE DRUG MARKET IN 2013 CHAPTER XIII ANALYSIS OF OPERATION CONDITIONS OF TYPICAL DOMESTIC AND FOREIGN DRUGS PRODUCTION CHAPTER XIV MARKET DEVELOPING PROSPECTS AND TRENDS ON CHINA'S MEDICATIONS FOR HEPATOPATHY FROM 2015 TO 2020 CHAPTER XV RESEARCH AND ANALYSIS OF CHINA'S LIVER DISEASE DRUG MARKET INVESTMENT FEASIBILITY FROM 2015 TO 2020 Companies Mentioned - AMERICAN MERCK & CO - Beijing Sl Pharmaceutical Co., Ltd. - Bristol-Myers Squibb - Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Fujian Cosunter Pharmaceutical Co. Ltd. - GlaxoSmithKline - Inner Mongolia Furui Medical Science Co. Ltd. - ROCHE - TIPR Pharmaceutical Responsible Company For more information visit http://www.researchandmarkets.com/research/lh...nalysis_of
GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
Novavax starts early stage Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 12:18PM CST
JNJ: 99.62 (+1.18), NVAX: 8.80 (+0.40), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
3 Hold-Rated Dividend Stocks: CYS, SIR, GSK
at The Street - Thu Feb 12, 9:30AM CST
These 3 dividend stocks are rated a Hold by TheStreet
SIR: 24.73 (-0.56), CYS: 8.78 (+0.04), GSK: 47.94 (+1.99)
5 Things GlaxoSmithKline PLC's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 12, 9:02AM CST
Source: GlaxoSmithKline, Facebook. The fourth quarter was another rough one for U.K.-based pharmaceutical giant GlaxoSmithKline . During the quarter, GlaxoSmithKline saw its revenue tumble 10% to $9.41 billion , inclusive of negative foreign...
JNJ: 99.62 (+1.18), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
European Venture Capitalists Celebrate Glaxo's Early Vaccines Move
EP Vantage - Seeking Alpha - Wed Feb 11, 3:47PM CST
GlaxoSmithKline's (NYSE: GSK ) $212m buyout of the Swiss vaccines player GlycoVaxyn will be celebrated in the offices of three European venture capitalists today. Since 2007 the company has raised $32m over two VC-backed rounds, equating to a...
GSK: 47.94 (+1.99)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Sports and Fitness Nutrition Supplements - Global Strategic Business Report 2015
M2 - Wed Feb 11, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/kzpfhr/sports_and) has announced the addition of the "Sports and Fitness Nutrition Supplements - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Sports and Fitness Nutrition Supplements in US$ Thousands by the following Segments: - Amino Acids/Derivatives - Herbal Products - Vitamins/Minerals - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 237 companies including many key and niche players such as: - Abbott Laboratories Inc. (US) - Champion Nutrition, Inc. (US) - Clif Bar & Company (US) - Dymatize Enterprises, Inc. (US) - Glanbia Plc (Ireland) - Optimum Nutrition, Inc. (US) - GlaxoSmithKline Plc (UK) - GNC Holdings, Inc. (US) - Herbalife International, Inc. (US) - NBTY, Inc. (US) - The Balance Bar Company (US) - Nestl? SA (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - PepsiCo Inc. (US) - Red Bull GmbH (Austria) - The Coca-Cola Co. (US) - Yakult Honsha Co., Ltd. (Japan) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET DYNAMICS 3. TRENDS AND ISSUES 4. PRODUCT INNOVATIONS: A CLOSER LOOK 5. PRODUCT OVERVIEW 6. PRODUCT INTRODUCTIONS/LAUNCHES 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT GLOBAL PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 237 (including Divisions/Subsidiaries 253) - The United States (173) - Canada (9) - Japan (3) - Europe (48) - France (2) - Germany (2) - The United Kingdom (30) - Rest of Europe (14) - Asia-Pacific (Excluding Japan) (15) - Latin America (1) - Africa (4) For more information visit http://www.researchandmarkets.com/research/kzpfhr/sports_and
HLF: 32.78 (-0.84), ABT: 46.09 (+0.87), GSK: 47.94 (+1.99), PEP: 99.13 (-1.14)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Glaxo Tries To Turn A Triple Play
EP Vantage - Seeking Alpha - Tue Feb 10, 12:47PM CST
There are several ways in which the treatment paradigm for chronic obstructive pulmonary disease could develop, and GlaxoSmithKline (NYSE: GSK ) has made a firm bet on one of them, yesterday starting a second pivotal trial combining a LAMA with a...
BIIB: 391.66 (-0.45), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Follicular Thyroid Cancer Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 11:31AM CST
The report "Follicular Thyroid Cancer - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer. Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/follicular-t...eport.html.
PFE: 34.64 (-0.23), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), EXEL: 2.48 (+0.20)
Tracking Tweedy Browne's Portfolio - Q4 2014 Update
John Vincent - at Seeking Alpha - Sat Feb 14, 11:31AM CST
KOF: 84.71 (+0.59), DNOW: 25.64 (+0.70), CNQ: 31.63 (+0.45), WMT: 85.81 (-0.08), GOOG: 549.01 (+6.08), DEO: 113.89 (-1.40), BSBR: 5.07 (+0.19), NOV: 53.36 (+0.80), FII: 35.09 (+0.20), CSCO: 29.43 (-0.03), MA: 87.14 (-0.38), PSX: 76.62 (+1.51), TMK: 54.05 (+0.35), UN: 42.28 (-0.30), HAL: 44.19 (+1.42), AGCO: 49.78 (+0.97), COP: 69.88 (+1.84), WFC: 55.33 (+0.47), GSK: 47.94 (+1.99), UL: 43.03 (-0.17), CTWS: 37.37 (-0.03), NWLI: 245.15 (+0.45), RDS.A: 66.32 (+0.97), ANAT: 104.90 (-0.10), BRK.B: 148.34 (-1.45), BRK.A: 222,555.00 (-1,905.00), NVS: 102.20 (-0.17), MMM: 165.94 (+0.03), LMT: 196.95 (-0.53), UNF: 121.82 (-0.50), XOM: 93.37 (+1.00), SHEN: 30.36 (+0.37), JNJ: 99.62 (+1.18), GOOGL: 551.16 (+5.15), BK: 39.20 (-0.21), UNP: 122.60 (-1.23), JOY: 44.14 (+0.35), DVN: 66.47 (+0.69), AXP: 78.08 (-2.40), EMR: 58.68 (+0.08), HSBC: 46.13 (-0.01), ITW: 98.26 (+0.48), PM: 82.87 (-0.82), BRO: 33.01 (+0.20), TOT: 54.14 (-0.36), USB: 45.07 (-0.05), BAX: 70.39 (+0.31), CMCSA: 59.47 (+1.09), VZ: 49.31 (-0.21)
The Fed Must Tolerate Higher Asset Prices To Achieve Higher Wages
Joe Leider - Seeking Alpha - Sat Feb 14, 12:45AM CST
I've been thinking a lot about inflation, banks and China. After reading "Gold, France, and the Great Depression, 1919-1932", I was wondering how the western world's "secular stagnation" could be related to China's rise. Before...
T: 34.66 (+0.05), GSK: 47.94 (+1.99), VZ: 49.31 (-0.21)
After Yesterday's Rally of 4.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Feb 13, 3:58PM CST
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $47.38 to a high of $47.96. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $46.30 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 47.94 (+1.99)
GlaxoSmithKline Set to Possibly Pullback After Yesterday's Rally of 4.33%
Comtex SmarTrend(R) - Fri Feb 13, 3:57PM CST
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $47.38 to a high of $47.96. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $46.30 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 47.94 (+1.99)
Jim Cramer's Stop Trading: Apache Has Room to Rise, J&J Takes It on the Chin
at The Street - Fri Feb 13, 12:19PM CST
Jim Cramer says independent energy company Apache is one to watch on great production, growth and a Merrill Lynch upgrade.
JNJ: 99.62 (+1.18), PXD: 157.85 (+9.71), APA: 67.05 (+2.47), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up
at Investor's Business Daily - Fri Feb 13, 9:41AM CST
Stocks opened higher in soft trade Friday as generally positive news out of Europe, rising oil prices and a welter of fourth-quarter earnings surprises bolstered early trade. The Nasdaq and the Dow Jones industrial average pulsed up 0.2% apiece. The...
VIP: 5.37 (+0.51), CAVM: 62.86 (-0.55), BIDU: 212.13 (+7.11), AKS: 4.87 (+0.39), TSM: 24.84 (+0.37), NTAP: 38.22 (+1.32), GSK: 47.94 (+1.99), X: 26.36 (+1.12), MT: 11.20 (+0.74)
GlaxoSmithKline +3.8% after UBS turns bullish
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:30AM CST
GSK: 47.94 (+1.99)
1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Upgrade Alert for GlaxoSmithKline (GSK)
Comtex SmarTrend(R) - Fri Feb 13, 6:57AM CST
GlaxoSmithKline (NYSE:GSK) was upgraded from Sell to Buy at UBS today. The stock closed yesterday at $45.95 on volume of 3.5 million shares, below average daily volume of 4.2 million. GlaxoSmithKline plc is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. The Group, which also provides laboratory testing and disease management services, specializes in treatments for respiratory, central nervous system, gastro-intestinal and genetic disorders
GSK: 47.94 (+1.99)
Analysis of Chinese Liver Disease Drug Industry 2015
M2 - Fri Feb 13, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/lh55pz/analysis_of) has announced the addition of the "Analysis of Chinese Liver Disease Drug Industry 2015" report to their offering. Liver disease drug market competition in China is fierce. China's liver disease drug market can be divided into imported drugs and home-made drugs according to the drug producing area. Imported drugs are mainly represented by GlaxoSmithKline and Bristol-Myers Squibb, etc.; the main production enterprises of home-made drugs include Chia Tai Tianqing Pharmaceutical Group, TIPR Pharmaceutical Responsible Company, Fujian Cosunter Pharmaceutical Company, etc. Hepatobiliary system drug has gradually become a variety that costs a large amount of money and it is the third largest one that ranks only second to anti-peptic ulcer and diabetes drug in the digestion metabolism category. In terms of the structure of drug, anti-viral drugs and free regulating drugs account for 30% of liver disease drug, auxiliary drugs account for 25% and Chinese medicine account for 36%. The sales volume of China liver disease drug in hospital market is increasing. Before 2009, as a result of the continuous introduction of new products, new specifications and new dosage form products, the growth of sales was comparatively large, while its growth began to slow down from 2010. On the one hand, it is due to the hepatitis B vaccination rate has been increased significantly in recent years and the decrease of the expansion speed of hepatitis B patients; on the other hand, the growth of sales has entered a smooth stage. The data issued by China Competition Information shows that, the scale of China liver disease drug market is close to RMB 43 billion in 2013. Key Topics Covered: CHAPTER I RELATED OVERVIEW OF LIVER DISEASE DRUG CHAPTER II ANALYSIS OF THE OPERATION SITUATION OF GLOBAL DRUGS FOR THE LIVER DISEASE MARKETS IN 2013 CHAPTER III ANALYSIS OF MARKET DEVELOPMENT ENVIRONMENT OF CHINA'S LIVER DISEASE DRUG INDUSTRY IN 2013-2014 SECTION IV THE LEVEL AND FEATURES OF LIVER DISEASE MEDICATION TECHNIQUE CHAPTER IV HEPATITIS INCIDENCE IN CHINA AND ANALYSIS OF THE STATISTICS OF ITS PREVALENCE IN 2013 CHAPTER V TYPES OF LIVER MEDICINE CHAPTER VI DEEP RESEARCH OF CHINA LIVER MEDICATION MARKET IN 2013 CHAPTER VII OBSERVATION ON DYNAMICS OF SEGMENT MARKET OF LIVER DISEASE DRUGS 2013 CHAPTER VIII CHINA HEPATITIS B VACCINE MARKET ANALYSIS IN 2013 CHAPTER IX COMPARATIVE ANALYSIS OF MAIN ANTI-HEPATITIS DRUGS IN CHINA IN 2012-2013 CHAPTER X CLINICAL APPLICATION OF LIVERISH RESEARCH RESULTS AND DYNAMIC TRACING OF THE NEWEST CHAPTER XI ANALYSIS OF DYNAMIC AND TREND COMPETITION FOR CHINA'S LIVER DISEASE DRUG MARKET IN 2013 CHAPTER XII SWOT ANALYSIS OF CHINA'S LIVER DISEASE DRUG MARKET IN 2013 CHAPTER XIII ANALYSIS OF OPERATION CONDITIONS OF TYPICAL DOMESTIC AND FOREIGN DRUGS PRODUCTION CHAPTER XIV MARKET DEVELOPING PROSPECTS AND TRENDS ON CHINA'S MEDICATIONS FOR HEPATOPATHY FROM 2015 TO 2020 CHAPTER XV RESEARCH AND ANALYSIS OF CHINA'S LIVER DISEASE DRUG MARKET INVESTMENT FEASIBILITY FROM 2015 TO 2020 Companies Mentioned - AMERICAN MERCK & CO - Beijing Sl Pharmaceutical Co., Ltd. - Bristol-Myers Squibb - Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Fujian Cosunter Pharmaceutical Co. Ltd. - GlaxoSmithKline - Inner Mongolia Furui Medical Science Co. Ltd. - ROCHE - TIPR Pharmaceutical Responsible Company For more information visit http://www.researchandmarkets.com/research/lh...nalysis_of
GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
Novavax starts early stage Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 12:18PM CST
JNJ: 99.62 (+1.18), NVAX: 8.80 (+0.40), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
3 Hold-Rated Dividend Stocks: CYS, SIR, GSK
at The Street - Thu Feb 12, 9:30AM CST
These 3 dividend stocks are rated a Hold by TheStreet
SIR: 24.73 (-0.56), CYS: 8.78 (+0.04), GSK: 47.94 (+1.99)
5 Things GlaxoSmithKline PLC's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 12, 9:02AM CST
Source: GlaxoSmithKline, Facebook. The fourth quarter was another rough one for U.K.-based pharmaceutical giant GlaxoSmithKline . During the quarter, GlaxoSmithKline saw its revenue tumble 10% to $9.41 billion , inclusive of negative foreign...
JNJ: 99.62 (+1.18), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
European Venture Capitalists Celebrate Glaxo's Early Vaccines Move
EP Vantage - Seeking Alpha - Wed Feb 11, 3:47PM CST
GlaxoSmithKline's (NYSE: GSK ) $212m buyout of the Swiss vaccines player GlycoVaxyn will be celebrated in the offices of three European venture capitalists today. Since 2007 the company has raised $32m over two VC-backed rounds, equating to a...
GSK: 47.94 (+1.99)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Sports and Fitness Nutrition Supplements - Global Strategic Business Report 2015
M2 - Wed Feb 11, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/kzpfhr/sports_and) has announced the addition of the "Sports and Fitness Nutrition Supplements - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Sports and Fitness Nutrition Supplements in US$ Thousands by the following Segments: - Amino Acids/Derivatives - Herbal Products - Vitamins/Minerals - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 237 companies including many key and niche players such as: - Abbott Laboratories Inc. (US) - Champion Nutrition, Inc. (US) - Clif Bar & Company (US) - Dymatize Enterprises, Inc. (US) - Glanbia Plc (Ireland) - Optimum Nutrition, Inc. (US) - GlaxoSmithKline Plc (UK) - GNC Holdings, Inc. (US) - Herbalife International, Inc. (US) - NBTY, Inc. (US) - The Balance Bar Company (US) - Nestl? SA (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - PepsiCo Inc. (US) - Red Bull GmbH (Austria) - The Coca-Cola Co. (US) - Yakult Honsha Co., Ltd. (Japan) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET DYNAMICS 3. TRENDS AND ISSUES 4. PRODUCT INNOVATIONS: A CLOSER LOOK 5. PRODUCT OVERVIEW 6. PRODUCT INTRODUCTIONS/LAUNCHES 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT GLOBAL PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 237 (including Divisions/Subsidiaries 253) - The United States (173) - Canada (9) - Japan (3) - Europe (48) - France (2) - Germany (2) - The United Kingdom (30) - Rest of Europe (14) - Asia-Pacific (Excluding Japan) (15) - Latin America (1) - Africa (4) For more information visit http://www.researchandmarkets.com/research/kzpfhr/sports_and
HLF: 32.78 (-0.84), ABT: 46.09 (+0.87), GSK: 47.94 (+1.99), PEP: 99.13 (-1.14)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Glaxo Tries To Turn A Triple Play
EP Vantage - Seeking Alpha - Tue Feb 10, 12:47PM CST
There are several ways in which the treatment paradigm for chronic obstructive pulmonary disease could develop, and GlaxoSmithKline (NYSE: GSK ) has made a firm bet on one of them, yesterday starting a second pivotal trial combining a LAMA with a...
BIIB: 391.66 (-0.45), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Follicular Thyroid Cancer Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 11:31AM CST
The report "Follicular Thyroid Cancer - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer. Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/follicular-t...eport.html.
PFE: 34.64 (-0.23), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), EXEL: 2.48 (+0.20)
